Predict your next investment

HEALTHCARE | Medical Devices & Equipment
parsortix.us

See what CB Insights has to offer

Founded Year

2006

Stage

Grant | Alive

Total Raised

$150K

Last Raised

$150K | 12 yrs ago

About Parsortix

Parsortix technology is a physical separation device that enables the user to capture particles of different types suspended in fluid media using a patented separation process. The device design can be 'tuned' to capture particles of different sizes and has a wide range of potential applications in medical devices and diagnostics. The device has been successfully shown to be capable of separating fetal cells from whole peripheral maternal blood, and to be capable of capturing and separating different kinds of white blood cells from whole blood.

Parsortix Headquarter Location

3711 Market Street University City Science Center, 8th Floor

Philadelphia, Pennsylvania, 19104,

United States

215-966-6240

Latest Parsortix News

ANGLE hails 'groundbreaking' research that underlines the potential of its liquid biopsy system in metastatic breast cancer

Jan 17, 2022

) ANGLE hails 'groundbreaking' research that underlines the potential of its liquid biopsy system in metastatic breast cancer Researchers at the University of Southern California Norris Cancer Center compared the information gleaned using ANGLE's Parsortix system with the insights from a traditional tissue biopsy ANGLE PLC (AIM:AGL, OTCQX:ANPCY) ’s liquid biopsy system could offer an alternative to traditional tissue biopsy to assess the spread and mutation of metastatic breast cancer. The company described as ‘ground-breaking’ research by the University of Southern California Norris Cancer Center that compared the two approaches. Not only did they find a ‘concordance’, or consistency between blood and tissue samples taken from patients when analysed, the scientists were also able to glean additional crucial detail from circulating tumour cells harvested using ANGLE’s Parsortix system. Specifically, Parsortix enabled longitudinal analysis of the cancer cells as they metastasised (spread from the original site) and mutated. Dr Julie Lang and her team at USC were even able to detect the changes that lead to resistance to anti-cancer therapies. This is important as it could help optimise the treatment given to women with metastatic breast cancer. It is also important to note that only 50% of people with the advanced form of the disease have successful tissue biopsies as they are either too ill to undergo the invasive procedure or the tissue site is inaccessible. So, as ANGLE pointed out in its press release: “A simple, repeatable liquid biopsy alternative using the Parsortix system could resolve the issues with metastatic tissue biopsies and, as the study finds, provide real time information on the cancer evolution to guide treatment options.” Quick facts: ANGLE PLC

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Parsortix Patents

Parsortix has filed 6 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/12/2013

4/25/2017

Nanotechnology, Molecular biology, Cell biology, Biotechnology, Clusters of differentiation

Grant

Application Date

11/12/2013

Grant Date

4/25/2017

Title

Related Topics

Nanotechnology, Molecular biology, Cell biology, Biotechnology, Clusters of differentiation

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.